Report cover image

Global Gastrointestinal Stromal Tumor Drug Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 126 Pages
SKU # APRC20340356

Description

Summary

According to APO Research, The global Gastrointestinal Stromal Tumor Drug market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Gastrointestinal Stromal Tumor Drug include China Biopharmaceuticals, Zai Lab, CSPC Pharmaceuticals, Novartis, Mylan Pharms Inc., Kelun Pharmaceuticals, CStone Pharmaceuticals, Hansoh Pharmaceuticals and Vannsh Life Sciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Gastrointestinal Stromal Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Stromal Tumor Drug.

The Gastrointestinal Stromal Tumor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gastrointestinal Stromal Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Gastrointestinal Stromal Tumor Drug Segment by Company

China Biopharmaceuticals
Zai Lab
CSPC Pharmaceuticals
Novartis
Mylan Pharms Inc.
Kelun Pharmaceuticals
CStone Pharmaceuticals
Hansoh Pharmaceuticals
Vannsh Life Sciences
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceuticals
MSN Laboratories
Glenmark Pharmaceuticals Ltd.
Drug International
Dr. Reddy's Laboratories
Deciphera Pharmaceuticals
Bulat Pharmaceutical
Beacon Pharmaceuticals
Bayer Pharmaceuticals
Apotex Inc.
Actavis Generics
Gastrointestinal Stromal Tumor Drug Segment by Type

Ripretinib
Regorafenib
Sunitinib
Imatinib
Others
Gastrointestinal Stromal Tumor Drug Segment by Application

Hospital
Clinic
Others
Gastrointestinal Stromal Tumor Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Stromal Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Stromal Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Stromal Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastrointestinal Stromal Tumor Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Gastrointestinal Stromal Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

126 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Gastrointestinal Stromal Tumor Drug Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Gastrointestinal Stromal Tumor Drug Sales Estimates and Forecasts (2020-2031)
1.3 Gastrointestinal Stromal Tumor Drug Market by Type
1.3.1 Ripretinib
1.3.2 Regorafenib
1.3.3 Sunitinib
1.3.4 Imatinib
1.3.5 Others
1.4 Global Gastrointestinal Stromal Tumor Drug Market Size by Type
1.4.1 Global Gastrointestinal Stromal Tumor Drug Market Size Overview by Type (2020-2031)
1.4.2 Global Gastrointestinal Stromal Tumor Drug Historic Market Size Review by Type (2020-2025)
1.4.3 Global Gastrointestinal Stromal Tumor Drug Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Gastrointestinal Stromal Tumor Drug Sales Breakdown by Type (2020-2025)
1.5.2 Europe Gastrointestinal Stromal Tumor Drug Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Breakdown by Type (2020-2025)
1.5.4 South America Gastrointestinal Stromal Tumor Drug Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Gastrointestinal Stromal Tumor Drug Industry Trends
2.2 Gastrointestinal Stromal Tumor Drug Industry Drivers
2.3 Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges
2.4 Gastrointestinal Stromal Tumor Drug Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Gastrointestinal Stromal Tumor Drug Revenue (2020-2025)
3.2 Global Top Players by Gastrointestinal Stromal Tumor Drug Sales (2020-2025)
3.3 Global Top Players by Gastrointestinal Stromal Tumor Drug Price (2020-2025)
3.4 Global Gastrointestinal Stromal Tumor Drug Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Gastrointestinal Stromal Tumor Drug Major Company Production Sites & Headquarters
3.6 Global Gastrointestinal Stromal Tumor Drug Company, Product Type & Application
3.7 Global Gastrointestinal Stromal Tumor Drug Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Gastrointestinal Stromal Tumor Drug Market CR5 and HHI
3.8.2 Global Top 5 and 10 Gastrointestinal Stromal Tumor Drug Players Market Share by Revenue in 2024
3.8.3 2023 Gastrointestinal Stromal Tumor Drug Tier 1, Tier 2, and Tier 3
4 Gastrointestinal Stromal Tumor Drug Regional Status and Outlook
4.1 Global Gastrointestinal Stromal Tumor Drug Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Gastrointestinal Stromal Tumor Drug Historic Market Size by Region
4.2.1 Global Gastrointestinal Stromal Tumor Drug Sales in Volume by Region (2020-2025)
4.2.2 Global Gastrointestinal Stromal Tumor Drug Sales in Value by Region (2020-2025)
4.2.3 Global Gastrointestinal Stromal Tumor Drug Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Gastrointestinal Stromal Tumor Drug Forecasted Market Size by Region
4.3.1 Global Gastrointestinal Stromal Tumor Drug Sales in Volume by Region (2026-2031)
4.3.2 Global Gastrointestinal Stromal Tumor Drug Sales in Value by Region (2026-2031)
4.3.3 Global Gastrointestinal Stromal Tumor Drug Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Gastrointestinal Stromal Tumor Drug by Application
5.1 Gastrointestinal Stromal Tumor Drug Market by Application
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Gastrointestinal Stromal Tumor Drug Market Size by Application
5.2.1 Global Gastrointestinal Stromal Tumor Drug Market Size Overview by Application (2020-2031)
5.2.2 Global Gastrointestinal Stromal Tumor Drug Historic Market Size Review by Application (2020-2025)
5.2.3 Global Gastrointestinal Stromal Tumor Drug Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Gastrointestinal Stromal Tumor Drug Sales Breakdown by Application (2020-2025)
5.3.2 Europe Gastrointestinal Stromal Tumor Drug Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Breakdown by Application (2020-2025)
5.3.4 South America Gastrointestinal Stromal Tumor Drug Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 China Biopharmaceuticals
6.1.1 China Biopharmaceuticals Comapny Information
6.1.2 China Biopharmaceuticals Business Overview
6.1.3 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.1.5 China Biopharmaceuticals Recent Developments
6.2 Zai Lab
6.2.1 Zai Lab Comapny Information
6.2.2 Zai Lab Business Overview
6.2.3 Zai Lab Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio
6.2.5 Zai Lab Recent Developments
6.3 CSPC Pharmaceuticals
6.3.1 CSPC Pharmaceuticals Comapny Information
6.3.2 CSPC Pharmaceuticals Business Overview
6.3.3 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.3.5 CSPC Pharmaceuticals Recent Developments
6.4 Novartis
6.4.1 Novartis Comapny Information
6.4.2 Novartis Business Overview
6.4.3 Novartis Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio
6.4.5 Novartis Recent Developments
6.5 Mylan Pharms Inc.
6.5.1 Mylan Pharms Inc. Comapny Information
6.5.2 Mylan Pharms Inc. Business Overview
6.5.3 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.5.5 Mylan Pharms Inc. Recent Developments
6.6 Kelun Pharmaceuticals
6.6.1 Kelun Pharmaceuticals Comapny Information
6.6.2 Kelun Pharmaceuticals Business Overview
6.6.3 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.6.5 Kelun Pharmaceuticals Recent Developments
6.7 CStone Pharmaceuticals
6.7.1 CStone Pharmaceuticals Comapny Information
6.7.2 CStone Pharmaceuticals Business Overview
6.7.3 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.7.5 CStone Pharmaceuticals Recent Developments
6.8 Hansoh Pharmaceuticals
6.8.1 Hansoh Pharmaceuticals Comapny Information
6.8.2 Hansoh Pharmaceuticals Business Overview
6.8.3 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.8.5 Hansoh Pharmaceuticals Recent Developments
6.9 Vannsh Life Sciences
6.9.1 Vannsh Life Sciences Comapny Information
6.9.2 Vannsh Life Sciences Business Overview
6.9.3 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio
6.9.5 Vannsh Life Sciences Recent Developments
6.10 Teva Pharmaceutical Industries Ltd.
6.10.1 Teva Pharmaceutical Industries Ltd. Comapny Information
6.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
6.10.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments
6.11 Sun Pharmaceuticals
6.11.1 Sun Pharmaceuticals Comapny Information
6.11.2 Sun Pharmaceuticals Business Overview
6.11.3 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.11.5 Sun Pharmaceuticals Recent Developments
6.12 MSN Laboratories
6.12.1 MSN Laboratories Comapny Information
6.12.2 MSN Laboratories Business Overview
6.12.3 MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
6.12.5 MSN Laboratories Recent Developments
6.13 Glenmark Pharmaceuticals Ltd.
6.13.1 Glenmark Pharmaceuticals Ltd. Comapny Information
6.13.2 Glenmark Pharmaceuticals Ltd. Business Overview
6.13.3 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.13.5 Glenmark Pharmaceuticals Ltd. Recent Developments
6.14 Drug International
6.14.1 Drug International Comapny Information
6.14.2 Drug International Business Overview
6.14.3 Drug International Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio
6.14.5 Drug International Recent Developments
6.15 Dr. Reddy's Laboratories
6.15.1 Dr. Reddy's Laboratories Comapny Information
6.15.2 Dr. Reddy's Laboratories Business Overview
6.15.3 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
6.15.5 Dr. Reddy's Laboratories Recent Developments
6.16 Deciphera Pharmaceuticals
6.16.1 Deciphera Pharmaceuticals Comapny Information
6.16.2 Deciphera Pharmaceuticals Business Overview
6.16.3 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.16.5 Deciphera Pharmaceuticals Recent Developments
6.17 Bulat Pharmaceutical
6.17.1 Bulat Pharmaceutical Comapny Information
6.17.2 Bulat Pharmaceutical Business Overview
6.17.3 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio
6.17.5 Bulat Pharmaceutical Recent Developments
6.18 Beacon Pharmaceuticals
6.18.1 Beacon Pharmaceuticals Comapny Information
6.18.2 Beacon Pharmaceuticals Business Overview
6.18.3 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.18.5 Beacon Pharmaceuticals Recent Developments
6.19 Bayer Pharmaceuticals
6.19.1 Bayer Pharmaceuticals Comapny Information
6.19.2 Bayer Pharmaceuticals Business Overview
6.19.3 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
6.19.5 Bayer Pharmaceuticals Recent Developments
6.20 Apotex Inc.
6.20.1 Apotex Inc. Comapny Information
6.20.2 Apotex Inc. Business Overview
6.20.3 Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
6.20.5 Apotex Inc. Recent Developments
6.21 Actavis Generics
6.21.1 Actavis Generics Comapny Information
6.21.2 Actavis Generics Business Overview
6.21.3 Actavis Generics Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio
6.21.5 Actavis Generics Recent Developments
7 North America by Country
7.1 North America Gastrointestinal Stromal Tumor Drug Sales by Country
7.1.1 North America Gastrointestinal Stromal Tumor Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Gastrointestinal Stromal Tumor Drug Sales by Country (2020-2025)
7.1.3 North America Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2026-2031)
7.2 North America Gastrointestinal Stromal Tumor Drug Market Size by Country
7.2.1 North America Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Gastrointestinal Stromal Tumor Drug Market Size by Country (2020-2025)
7.2.3 North America Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Gastrointestinal Stromal Tumor Drug Sales by Country
8.1.1 Europe Gastrointestinal Stromal Tumor Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2020-2025)
8.1.3 Europe Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2026-2031)
8.2 Europe Gastrointestinal Stromal Tumor Drug Market Size by Country
8.2.1 Europe Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Gastrointestinal Stromal Tumor Drug Market Size by Country (2020-2025)
8.2.3 Europe Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales by Country
9.1.1 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales by Country (2020-2025)
9.1.3 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size by Country
9.2.1 Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Gastrointestinal Stromal Tumor Drug Sales by Country
10.1.1 South America Gastrointestinal Stromal Tumor Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Gastrointestinal Stromal Tumor Drug Sales by Country (2020-2025)
10.1.3 South America Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2026-2031)
10.2 South America Gastrointestinal Stromal Tumor Drug Market Size by Country
10.2.1 South America Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Gastrointestinal Stromal Tumor Drug Market Size by Country (2020-2025)
10.2.3 South America Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country
11.1.1 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2020-2025)
11.1.3 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country
11.2.1 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Gastrointestinal Stromal Tumor Drug Value Chain Analysis
12.1.1 Gastrointestinal Stromal Tumor Drug Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Gastrointestinal Stromal Tumor Drug Production Mode & Process
12.2 Gastrointestinal Stromal Tumor Drug Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Gastrointestinal Stromal Tumor Drug Distributors
12.2.3 Gastrointestinal Stromal Tumor Drug Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.